psoriatic arthritis

Showing 15 posts of 16 posts found.

NHS building

Abbvie psoriatic arthritis drug approved for use in Scotland

May 11, 2021
Manufacturing and Production AbbVie, NHS, arthritis, psoriatic arthritis

Abbvie’s RINVOQ (upadacitinib) drug, for the treatment of active psoriatic arthritis (PsA) in adults, has been approved for use in …


Janssen’s Tremfya shows skin clearance benefit for psoriatic arthritis patients in two Phase 3 studies

June 4, 2020
Research and Development Janssen, Tremfya, psoriatic arthritis

Janssen has revealed data from two Phase 3 trials for Tremfya (guselkumab), showing improvement in skin clearance and symptoms in …


AbbVie’s Rinvoq hits target in psoriatic arthritis sub-population at Phase 3

February 6, 2020
Research and Development AbbVie, Rinvoq, pharma, psoriatic arthritis

AbbVie has unveiled new Phase 3 data on its selective and reversible JAK inhibitor Rinvoq (upadacitinib) in the treatment of …


Novartis’ Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows

October 10, 2019
Research and Development Cosentyx, Novartis, pharma, psoriatic arthritis

Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs …

NICE recommends Eli Lilly’s psoriatic arthritis drug

August 9, 2018
Research and Development, Sales and Marketing Eli Lilly, England, NICE, Wales, psoriatic arthritis

Eli Lilly have announced that the monoclonal antibody ixekizumab, has been recommended by NICE for use as a treatment option …

Pfizer’s Xeljanz scores EU approval for active psoriatic arthritis

June 29, 2018
Medical Communications, Sales and Marketing EU, Europe, Pfizer, Xeljanz, pharma, psoriatic arthritis

Pfizer has announced that the European Commission (EC) has approved Xeljanz in combination with methotrexate (MTX) for the treatment of …


Eli Lilly’s Taltz get EU approval in psoriatic arthritis subgroup

January 24, 2018
Research and Development, Sales and Marketing EU, Eli Lilly, Europe, European Commission, Taltz, pharma, psoriatic arthritis

Eli Lilly has revealed that its IgG4 monoclonal antibody Taltz (ixekizumab) has been awarded marketing approval from the European Commission …

FDA approves Pfizer’s Xeljanz for psoriatic arthritis

December 18, 2017
Sales and Marketing FDA, Pfizer, Xeljanz, pharma, psoriatic arthritis

Pfizer has revealed that the FDA has passed marketing approval for Xeljanz (tofacitinib) for the treatment of active psoriatic arthritis …


Celgene’s Otezla hits primary endpoint in psoriatic arthritis study

November 15, 2016
Manufacturing and Production, Research and Development Celgene, otezla, psoriatic arthritis

Celgene has unveiled new data on its selective inhibitor of phosphodiesterase 4 (PDE4) Otezla (apremilast) which shows that the treatment …

Novartis reveals positive three-year efficacy data for psoriatic arthritis drug

November 15, 2016
Manufacturing and Production, Research and Development Cosentyx, Novartis, psoriatic arthritis

Novartis has claimed that its Cosentyx (secukinumab) treatment is now the first approved fully human interleukin-17A (IL-17A) inhibitor to demonstrate …


Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial

April 5, 2016
Medical Communications, Research and Development, Sales and Marketing Allergan, Pfizer, Xeljanz, merger, phase III, psoriatic arthritis, tofacitinib

Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial …

New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs

December 16, 2015
Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin

NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …


Novartis’ Cosentyx gets European approval for two conditions

October 23, 2015
Medical Communications, Sales and Marketing Cosentyx, European Medicines Agency, Novartis, psoriatic arthritis

The scientific committee of the European Medicines Agency (EMA) has recommended the approval of Novartis’ Cosentyx (secukinumab) for treatment of ankylosing …

Abbvie image

AbbVie highlights treatment adherence

June 12, 2014
Sales and Marketing ALIGN, AbbVie, Abbott, Crohn’s disease, TNF, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, treatment, ulcerative colitis

Patients with inflammatory diseases tend to be better at following their treatment regimes with TNF inhibitors rather than other medicines, …

Abbott launches ‘Outside In’ initiative for psoriatic arthritis

March 21, 2012
Medical Communications, Sales and Marketing Abbott, Outside In, dermatology, med ed, psoriatic arthritis

An expert group of rheumatologists and dermatologists have come together with Abbott to develop new clinical tools for psoriatic arthritis …

Latest content